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ABSTRACT
Objectives: To describe the characteristic of bladder transitional cell cancer (TCC). Material & methods: We reviewed the 
medical records of patients with bladder TCC admitted in Soetomo General Hospital Surabaya, from January 2008 until 
December 2012. The data regarding demographic characteristics, clinical presentation and staging, grading and staging 
based on pathological examinations results, and the management of the cancer. Results: The 126 cases, consisted of 102 
men (81%) and 24 women (19%) with its ratio was 4.2 : 1. All male patients were heavy cigarette smokers. Mean age was 
57.8 years, peak incidence was 50-59 years. Hematuria was the most frequent clinical presentation (112 patients, 88.9%), 
urinary retention and other complaints (12 patients, 9.5%), and chronic dysuria (2 patients, 1.6%). Clinical staging was T1 
as NMIBC in 7 patients (5.7%). MIBC consisted of T2 in 37 patients (30.3%), T3 in 35 patients (28.7%), T4 in 43 patients 
(35.2%). The pathological grading as an high-grade were 74 patients (64.3%). All patients had underwent TURBT for 
diagnosis and staging, followed by definitive treatment. It consisted of TURBT and chemotherapy bladder instillation in 7 
patients (5.6%), radical cystectomy in 13 patients (10.3%), EBRT in 5 patients (4%), MVAC chemotherapy in 24 patients 
(19%), EBRT and chemotherapy with MVAC in 3 patients (2.4%). There were 74 patients (58.7%) underwent TURBT alone. 
Conclusion: Bladder TCC was in advanced stage when diagnosed, most of the patients received only TURBT and refused 
further treatment.
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ABSTRAK
Tujuan: Menggambarkan karakteristik kanker buli. Bahan & cara: Kami secara retrospektif meninjau rekam medis pasien 
dengan sel kanker buli yang masuk di RSUD Dr. Soetomo Surabaya antara Januari 2008 sampai Desember 2012. Data 
tersebut meliputi karakteristik demografi, presentasi klinis, dan staging saat didiagnosa, grading dan staging berdasarkan 
pemeriksaan patologi, dan juga manajemen kanker. Hasil: Dari total 126 kasus, terdiri dari 102 laki-laki (81%) dan 24 
wanita (19%), dengan rasio laki-laki dan wanita 4.2 : 1. Semua pasien laki-laki adalah perokok berat. Rerata umur adalah 
57.8 tahun dengan puncak insiden ditemukan pada umur 50-59 tahun. Hematuria adalah sebagian besar presentasi klinis 
umum (112 pasien, 88.9%), diikuti retensi urine dan keluhan lain (12 pasien, 9.5%), dan disuria kronis (2 pasien, 1.6%). 
Staging klinis pasien saat didiagnosa adalah 7 pasien (5.7%) pada T1 sebagai NMIBC. MIBC terdiri dari T2 pada 37 
pasien (30.3%), T3 pada 35 pasien (28.7%), dan T4 pada 43 pasien (35.2%). Grading patologi pada grade tinggi 74 pasien 
(64.3%). Semua pasien telah menjalani TURBT untuk diagnosa dan staging, diikuti oleh perawatan definitif. Perawatan 
definitif terdiri dari TURBT dan kemoterapi instilasi kandung kemih pada 7 pasien (5.6%), radikal sistektomi pada 13 
pasien (10.3%), EBRT pada 5 pasien (4%), kemoterapi dengan MVAC pada 24 pasien (19%), EBRT dan kemoterapi 
dengan MVAC pada 3 pasien (2.4%). Terdapat 74 pasien (58.7%) yang hanya menjalani TURBT. Simpulan: Kanker buli 
dalam stase awal saat didiagnosa dan sebagian besar pasien menerima hanya TURBT dan menolak perawatan lebih 
lanjut.
Kata kunci: Kanker buli, karakteristik, manajemen.
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INTRODUCTION
The incidence of carcinoma of the bladder 
(CaB) in men is 10.1 per 100.000 population while 
1its incidence in women is 2.5.  Based on Globocan 
Data, 2008, the incidence of CaB patients in 
Indonesia for men and women per 100.000 
2population were 4.9-10.6 and 1.2-1.8, respectively.
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Risk for CaB is doubled for people who have 
family history of CaB. The risk factors for CaB are 
cigarrete smoking, exposure to carcinogens, 
nutritional factors, environmental pollution, 
socioeconomic status, race, gender, and certain 
medical conditions such as diabetes mellitus and 
3schistosomiasis.  Cigarette smoking is a major risk 
factor for the occurrence of the CaB. The incidence 
of CaB four times lower in women, while mortality is 
3,4higher than men.
CaB can be staged according to clinical 
parameters of tumor, node, and metastasis (TNM).5 
For purpose of treatment options, it can also be 
classified as non-muscle invasive bladder cancer 
(NMIBC) and muscle-invasive (MIBC). According 
to cellular differentiation, CaB can be classified into 
urothelial papilloma, grade 1 (well differentiated), 
grade 2 (moderately differentiated), and grade 3 
6(poorly differentiated).
A classic symptom for CaB is gross 
hematuria (occult), painless, and intermittent. This 
triad of hematuria is found in 80% of CaB patients. 
Approximately 10% of complaints are caused by the 
process of metastasis. Dysuria and other irritative 
complaints are found in approximately 30% of CaB 
7patients.  Imaging examination for detection of CaB 
include intravenous pyelography (IVP), ultrasound, 
and Computed Tomography (CT) scan or Magnetic 
6-9Resonance Imaging (MRI).  The sensitivity of urine 
cytology is very varied ranging from 28-100%, 
which is quite sensitive to high-grade tumors and 
CIS and often give negative results on the low-grade 
7 , 1 0 - 1 2of tumors.  BTA stat,  NMP22, ucyt 
+/immunoCyt, UroVysion FISH, and microsatellite 
analysis are some of the tumor markers for CaB that 
has been studied and researched. Sensitivity and 
specificity of that five markers for the detection of 
CaB are still too low when compared with 
10-12cystoscopy as the gold standard.  Combined with 
urine cytology and pathology examination results, 
cystoscopy is the gold standard for diagnosis of CaB, 
6,8,9,13CIS, and others bladder tumors.
Therapeutic modalities for CaB may be 
TURBT (Transurethral Resection of Bladder 
Tumor), radical cystectomy, local or systemic 
chemotherapy, radiotherapy, or combination of 
these. The choice of therapy is determined by tumor 
staging and pathology, as well as the condition of the 
individual patient (fit or unfit).6 For NMIBC, 
TURBT followed by intravesical instillation of 
14 cytostatic is a main strategy. Radical cystectomy 
with or without adjuvant therapy provide a good 
survival rate and low local recurrence for organ 
confined or nonorgan-confined MIBC with 
14-17negativenodes.  For locally advanced or 
metastatic CaB, cisplatin-based combination 
chemotherapy or gemcitabine/cisplatin provide 
long-term survival and reduce progression rate. Its 
lower toxicity making gemcitabine/cisplatin as a 
new standard chemotherapy regimen and replacing a 
classic MVAC (Methotrexate, Vinblastine, 
16,18,19Adriamycin, Cisplatin) regimen.
Radiotherapy is an alternative to the radical 
cystectomy, especially for older patients and whom 
with high-risk (unfit) for the complications of 
16,20operation.  The addition of chemotherapy 
fluorouracil and mitomycin C versus standard-dose 
radiotherapy is associated with decreased 
locoregional recurrence rate with no significant 
20toxicity.
OBJECTIVE
 
To describe the characteristic of patients 
with bladder transitional cell cancer (TCC) who 
admitted in Soetomo General Hospital Surabaya, 
from January 2008 until December 2012.
MATERIAL & METHOD
This is a retrospective and descriptive study 
design. The entire medical records of patients with 
CaB hospitalized in The Department of Urology 
Soetomo General Hospital Surabaya, between 
January 2008 and December 2012 were collected 
and analyzed. Variables collected were demographic 
aspects including number of patients, age, gender, 
ratio of men to women, risk factors of smoking; 
diagnostic aspects include chief of complaint, urine 
cytology and tumor markers, clinical staging, tumor 
grading and pathology examination results, as well 
as the therapeutic aspects. The collected data were 
analyzed to determine overall number of CaB, ratio 
between men and women patients,  age 
characteristics, percentage of heavy smokers (more 
than 2 packsper day), patient chief complaints, stage, 
and grading of histopathology results, as well as 
treatment performed. All analysis results are 
displayed in tables and described narratively.
RESULTS
During the period of January 2008 until 
December 2012, there were 126 patients with CaB 
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hospitalized in the Department of Urology Soetomo 
General Hospital Surabaya. They consisted of 102 
men (80.9%) and 24 women (19.1%). The ratio of 
men to women was 4.2 : 1. The average age of 
patients was 57.8 years. The age of majority was in 
the range of 50-59 years. All patients had a history of 
smoking in men, whereas no women smoked. When 
compared with all CaB patients, smoking history 
was present in 80.2% of cases.
The chief of complaint for the majority of 
the patients is gross, painless, intermittent hematuria 
(112 patients, 88.9%), urinary retention or other 
complaints (12 patients, 9.5%), and chronic dysuria 
(2 patients, 1.6%). Urine cytology was performed in 
102 patients (81%) showing negative results or no 
malignant cells (78 patients; 76.5%), atypical cells 
(14 patients; 13.5%) and malignant cells (10 
patients; 9.8%). The examination of tumor markers 
was only done in 2 patients (1.5%).
Table 1. Chief complaints.
Chief complaints  Number Percentage 
Gross, painless,
intermitten hematuria  112 88.9 
Chronic dysuria 2 1.6 
Urinary retention 
and others
 12 9.5 
Table 2. Urine cytology results.
Class
 
Number
 
Percentage
 
1 (normal/negative) 78 76.5 
2 (inflammatory cells) 0 0 
3 (atypical) 14 13.7 
4 (suggested 
   malignant cells)
 0 0 
5 (malignant cells) 10 9.8 
The majority of CaB patients was in 
advanced stage, above T2 when diagnosed (115 
patients, 91.3%). The details are T2 in 37 patients 
(30.3%), T3 in 35 patients (28.7%), and T4 in 43 
patients (35.3%). The early stage (T1) and classified 
as NMIBC is 7 patients (5.7%). There are 4 patients 
(3.6% of all samples) were no data in the medical 
record
Table 3. Stage of tumor.
Stage  Number Percentage 
T1 7 5.7 
T2 37 30.3 
T3 35 28.7 
T4 43 35.3 
No data 4 3.6 
Based on histopathology grading, 74 
patients have poorly differentiated tumors (high-
grade; 64.3%), 16 patients with moderate 
differentiation (moderate-grade, 14%), and 25 
patients with well-differentiated (low-grade, 
21.7%). There were 11 patients (8.7% of all samples) 
not recorded in the medical record. According to 
muscle invasion, 108 patients (85.7%) showed a 
pathology result as muscle-invasive while 8 patients 
(6.3%) had no evidence of muscle invasion. Ten 
patients (8% of all samples) had no data recorded.
Table 4. Histopathology grading.
Grade Number Percentage 
High grade 74 64.3 
Moderate grade 16 14 
Low grade 25 21.7 
No data 11 8.8 
Table 5. Invasion to muscle.
Invasion to muscle  Number  Percentage  
Yes  108 85.7 
No 8 6.3 
No data  10 8 
In the aspect of therapy, all patients 
underwent TURBT procedure to confirm the 
diagnosis and stage, as well as to determine the next 
definitive treatment options. The  definitive therapy 
consisting of TURBT followed by intravesical 
instillation of cytostatic agents, radical cystectomy, 
radiotherapy, chemotherapy, and chemoradio-
therapy. There are 7 patients (5.6%) who underwent 
intravesical instillations. Radical cystectomy 
performed in 13 patients (10.3%), radiotherapy in 5 
patients (4%), systemic chemotherapy with MVAC 
regimen in 24 patients (19%), and combination of 
radiotherapy and MVAC chemotherapy in 3 patients 
(2.4%). There are 73 patients (57.9%) who only 
underwent TURBT procedure as palliative therapy 
without any other definitive therapy followed.
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Table 6. Therapy.
Therapy  Number Percentage 
TURBT + intravesical cytostatic instillation 7 5.6 
Radical cystectomy 13 10.3 
Radiotherapy 5 4 
MVAC chemotherapy 24 19 
MVAC chemotherapy and radiotherapy 3 2.4 
TURBT only 74 58.7 
Variables  Total Percentage (%) Comments 
Total patients 
      Men; Women 
      Ratio men : women 
      Mean age; Mode of Age Group 
126 
102; 24 
4.2 : 1 
 
 
81; 19 
 
 
 
57.8 yo; 50-59 yo 
Smoking history 
      Men; Women 
 
102; 0 
 
81; 0 
 
Chief complaint 
      Gross, painless, intermittent hematuria 
      Chronic dysuria 
      Urinary retention and others 
 
112 
2 
12 
 
88.9 
1.6 
9.5 
 
Clinical staging 
      T1; T2 
      T3; T4 
 
7; 37 
35; 43 
 
5.7; 30.3 
28.7; 35.3 
4 patients (3.2%)  
no data 
Histopathology grading 
      High grade 
      Moderate grade 
      Low grade 
 
74 
16 
25 
 
64.3 
13.9 
21.7 
11 patients (8.7%)  
no data 
Invasion to muscle 
      Yes; No 
 
108; 8 
 
85.7; 6.3 
10 patients (7.9%)  
no data 
Definitive treatment 
      TURBT + intravesical cytostaticinstillation  
      Radical cystectomy 
      Radiotherapy 
      MVAC Chemotherapy 
      Radiotherapy and MVAC  chemotherapy 
      TURBT only 
 
7 
13 
5 
24 
3 
74 
 
5.6 
10.3 
4 
19 
2.4 
58.7 
 
Table 7. Profile of CaB patients.
Table 7 shows the profile of CaB patients in 
the Department of Urology Soetomo General 
Hospital Surabaya period January 2008 until 
December 2012.
DISCUSSION
Based on the results obtained, the ratio of 
men to women with CaB was 4.2 : 1. This result is not 
much different from Ploeg et al. They mentioned that 
risk of developing CaB for men is 1 in 25, while for 
women is 1 in 80. This means the ratio of men to 
1women to be exposed to the CaB is 3.2 : 1.  In 
Europe, it was reported that the incidence of CaB for 
men is 27 per 100.000 population, while for women 
is 6 per 100.000 population. In general, the 
worldwide incidence of CaB in men is 9 per 100.000 
population and in women is 2 per 100.000 
population, which means the men to women ratio is 
64.5 : 1.
Smoking is a major risk factor and is 
strongly correlated with the CaB. Based on the 
results obtained, all men with CaB were heavy 
smokers (more than 2 packs per day) whereas in all 
5women patients had no smoking history. Compared 
to all CaB patients, smoking history was found in 
81% of the cases. Burger et al states that the risk 
ofCaB for men smokers was 50-60% and for women 
3smokers was 20-30%.  Compared to non-smokers, 
the risk of those who have a history of smoking 
(former smoker) and current smokers to get CaB is 
32.22 and 4.06 times higher.  There were not any 
history of smoking for all women patients in this 
study. This can be explained that the occurrence of 
CaB in those patients may be due to predominantly 
other risk factors such a genetic factor or exposure to 
cigarette smoke (passive smoker).
Based on the results obtained, gross, 
painless, and intermittent hematuria as a chief 
complaint is most commonly found in CaB patients 
(88.9%), followed by urinary retention and chronic 
dysuria (9.5% and 1.6%). Siroky et al, states that the 
classic symptoms of a CaB that is gross (occult), 
painless (no pain), and intermittent hematuria exist 
7in 80% of CaB patients.  Approximately 10% of 
complaints are caused by the process of metastasis. 
Dysuria and other irritating complaints found in 
7approximately 30% of CaB patients.
Urine cytology performed on 102 patients 
(81%), the remainder (19%) are not documented in 
the medical record. Examination of tumor marker 
has not become a routine protocol in The Department 
of Urology Soetomo General Hospital Surabaya. 
NMP22 examination in 2 patients (1.5%) was 
performed as part of other studies on the diagnostic 
value for detection of CaB.
Based on the results obtained, CaB patients 
was in the advanced stage when diagnosed (above 
T2 in 115 patients, 94.3%). In detail, T2 in 37 
patients (30.3%), T3 in 35 patients (28.7%), and T4 
in 43 patients (35.2%). While 7 patients (5.7%) 
diagnosed at an early stage (T1) and classified as 
NMIBC is. There were 4 patients (3.2%) not 
recorded in the medical record of the tumor stage. 
These are consistent with the results of 
histopathology grading examination and description 
of tumor invasion into the muscle. The pathology 
examination of tumor tissue resected from TURBT 
procedure showed 74 patients in poorly 
differentiated (high-grade, 64.3%), 16 patients in 
moderately differentiated (moderate-grade, 13.9%), 
and 25 patients with well-differentiated (low-grade, 
21.7%). There were 11 patients (8.7%) with no data 
recorded about their pathology grading. According 
to the invasion of muscle, 108 patients (85.7%) 
showed a muscle-invasive bladder cancer whereas 8 
patients (6.3%) had not. Ten patients (7.9%) were no 
data about their muscle invasion.
Based on the data above, the results of 
clinical staging and histopathology grading showed 
a significant differences with the literature. Burger, 
Babjuk, Stenzl, et al, states that approximately 75% 
of newly diagnosed cases of CAB is in the non-
invasive stage. The remaining (25%) are cases of 
CaB newly diagnosed in advaced stage (muscle-
3,6,16invasive).  Such differences may be caused by the 
high awareness of the health, access to better health 
services, early detection rates in European countries 
and America compared to emerging countries such 
in Indonesia.
All CaB patients underwentTURBT 
procedure to confirm the diagnosis and staging, as 
well as to determine the next definitive treatment 
options. TURBT procedure is the main protocols and 
mandatory to performed in The Department of 
Urology Soetomo General Hospital Surabaya for 
patients who are clinically diagnosed CaB. The 
definitive therapy consisting of TURBT followed by 
intravesical instillation of cytostatics, radical 
cystectomy, radiotherapy, chemotherapy, and 
chemoradiotherapy. There were 7 patients (5.6%) 
who underwent intravesical instillation of 
cytostatics. In contrast to the literature or other 
international guidelines using Mitomycin C,6,8,9,16 
intravesical chemotherapy used in The Department 
of Urology Soetomo General Hospital is Epirubic in 
due to availability in  social health insurance 
medication list (Jamkesmas, People Health 
Insurance).
Radical cystectomy was performed in 13 
patients (10.3%), on average 3 procedures of 
cystectomy with Bricker's urinary diversion or 
neobladder was performed annually. Radiotherapy is 
performed in 5 patients (4%), the combination of 
radiotherapy and MVAC chemotherapy is in 3 
patients (2.4%). Radiotherapy as definitive therapy 
for patients with locally advanced CaB (T3 and T4) 
who are unfitor refused radical operation seems 
suitable. Because of limited facilities resulting in 6 
months queue for radiotherapy, patients were also 
offered systemic chemotherapy.
According to T-stage and histopathology 
grading, actually most of the patients need a radical 
treatment such as radical cystectomy or curative 
external radiotherapy but in fact many patients 
refused that treatment option.
Systemic chemotherapy is performed in 24 
patients (19%). Chemotherapy regimens used are 
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classic MVAC regimens. Based on the literature and 
16,18,19other international guidelines,  because of low 
toxicity, gemcitabine/cisplatin is becoming a new 
standard in CaB chemotherapy regimens. This can 
not be applied to the patients treated in The 
Department of Urology Soetomo General Hospital 
Surabaya. The reason is the high cost of the regimens 
and are not covered by health insurance 
(Jamkesmas), as well as the availability of 
preparations of gemcitabine in the hospital. 
Meanwhile, there were 74 patients (58.7%) who only 
underwent TURBT procedure. This is the most 
frequent treatment that performed to the CaB 
patients. Refusal of further treatment by the patients, 
palliative treatment, loss of control, died, or not 
recorded in the medical record are several reasons 
that can be explained for the patients who underwent 
only TURBT without any others definitive 
treatments.
CONCLUSION
Based on this study, we conclude that the 
characteristics and management of bladder cancer in 
Urology Department Soetomo General Hospital 
Surabaya were in advanced stage when diagnosed 
and most of the patients received only TURBT and 
refused any further definitive treatments.
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